Effect of Sublingual Fentanyl on Breathlessness in COPD
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
There is actually no physiologic or clinical data in the literature to clearly define the
potential benefits and side effects of sublingual fentanyl in patients with COPD. Therefore,
the purpose of this study is to test the hypothesis that sublingual fentanyl will improve
exercise capacity and dyspnea control in severe COPD patients experiencing persistent
breathlessness despite optimal management.